What is the Biotechnology Act?
Bioteknologiloven (the Norwegian Biotechnology Act) regulates the human-medical use of biotechnology in Norway. It covers rules for assisted reproduction, use of donor sperm/eggs, embryo-related procedures, and other tightly regulated medical applications where human cells and reproductive material are involved.
Why DBN tracks this law
Biotechnology law is not “just medicine” — it becomes family law the moment a child is born. Rules about donors, identity information, parentage recognition, and cross-border fertility services directly affect children’s rights and parents’ legal security. When the framework is unclear (or mismatched with realities abroad), children can end up in identity and documentation limbo.
Core policy pillars
- Consent and safety: strict requirements for consent, medical standards, and clinic responsibility.
- Donor identity transparency: Norway moved away from anonymous donation; donor-conceived people can have legally protected access to identity information under specific conditions.
- Clear prohibitions: the law sets boundaries, including the continuing prohibition of surrogacy in Norway.
Identity rights: donor conception
Norway’s donor conception rules are often discussed in terms of an identity-rights model: donor anonymity is not the default. Official guidance explains that people conceived with donor sperm in Norway after a defined date can request the donor’s identity when they reach adulthood (subject to the conditions in the scheme).
Do Better Norge perspective
DBN’s focus is child-centered transparency. Whenever the state regulates reproduction, it must also protect the child’s later right to health history and identity information. At the same time, law and administration must avoid creating preventable insecurity for families who used lawful treatment abroad but face documentation friction when returning to Norway.
Comments (0)
You must be logged in to comment Login
No comments yet. Be the first to start the conversation.